AACR 2024 | Do biomarkers exist for predicting response to CAR T-cell therapy?
The field of CAR T-cell therapy is rapidly evolving, and there is a need to identify factors that allow for predicting the response of patients to CAR-T. Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discusses the factors associated with poor outcomes, including high tumor burden, impaired T-cell fitness, tumor antigen expression, and composition of the tumor microenvironment. Dr Ruella highlights that, unfortunately, no predictive biomarkers exist at present, but these would be beneficial when selecting patients who would respond well to CAR-T. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
